UBS Maintains Buy on Guardant Health, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Dan Leonard has maintained a Buy rating on Guardant Health and raised the price target from $32 to $40.

August 21, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Dan Leonard has maintained a Buy rating on Guardant Health and increased the price target from $32 to $40, indicating a positive outlook.
The increase in price target from $32 to $40 by UBS suggests a positive outlook for Guardant Health, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100